Your Device Probably Has an Indian Predicate. You Just Haven't Found It Yet.
The Predicate Device Search Most Manufacturers Never Do — How Rule 51(5) of MDR 2017 Can Replace a 5-Year Pathway With a 9-Month One
By Ankur Khare — Biomedical Engineer | Regulatory Affairs Specialist | Founder, MedReg Intel
There is a question that should be the first question in every Indian medical device regulatory strategy conversation.
It is almost never asked.
The question is this: does a predicate device already exist in India for your product?
The answer to that question determines whether your regulatory pathway to the Indian market takes nine months or five years. It determines whether your application requires clinical investigation in India or not. It determines whether you file Form MD-14 or Form MD-26 — and the commercial, financial, and strategic consequences of those two pathways are not comparable.
Most manufacturers default to MD-26 — the investigational device pathway — without systematically checking whether a predicate device exists in India that would qualify them for a faster route. Some do it because their regulatory advisor recommended it without conducting the search. Some do it because they assume their device is novel enough that no Indian predicate could exist. Some do it because they simply do not know that Rule 51(5) of MDR 2017 creates a substantial equivalence pathway that changes the regulatory calculation entirely.
This article explains what that pathway is, how to find a predicate device that most manufacturers miss, and what a credible substantial equivalence argument actually looks like under Indian law.
The Timeline Gap That Makes This Question So Important
To understand why the predicate device question matters so much it helps to understand the timeline difference between the two pathways it determines.
The MD-26 pathway — for investigational medical devices without a predicate — runs through Chapter VIII of MDR 2017. It requires completion of clinical investigation under Chapter VII before the MD-26 application can be filed. Clinical investigation means Ethics Committee approval, CDSCO permission in Form MD-22 or MD-23, enrolled participants, safety monitoring, adverse event reporting, and a completed investigation report. That process extends over multiple years for most devices. The MD-26 application itself then takes up to 150 days — 120 days plus a 30-day extension — for CDSCO to decide.
Total realistic timeline from decision to market for a device without a predicate: three to five years minimum.
Cost: crores.
Complexity: sustained regulatory management throughout.
The MD-14 pathway — for devices with a predicate through the import licence route, or the manufacturing licence route for domestic manufacturers — does not require clinical investigation for devices with reference country approval under Rule 36(3), or for devices where substantial equivalence to an Indian predicate is established. The import licence decision timeline under Rule 36(1) is nine months.
The same device. The same market. The same CDSCO. Nine months versus five years — determined by whether a predicate device exists and whether a credible substantial equivalence argument can be made.
That is why the predicate device search is the first question.
What MDR 2017 Says About Predicate Devices
Rule 3(zm) of MDR 2017 defines predicate device with precision:
"predicate device means a device, first time and first of its kind, approved for manufacture for sale or for import by the Central Licensing Authority and has the similar intended use, material of construction, and design characteristics as the device which is proposed for licence in India."
Three elements constitute a predicate device under this definition.
First — it must have been approved by the Central Licensing Authority. State Licensing Authority approvals do not qualify. Only CLA — CDSCO — approved devices constitute valid predicates.
Second — it must be the first of its kind. The predicate is the originating approved device in a category. Subsequent devices approved based on that predicate are not themselves predicates for further applications — the chain traces back to the original CLA-approved device.
Third — it must have similar intended use, material of construction, and design characteristics as the device being proposed for licence.
The third element is where the substantial equivalence analysis lives — and where most of the strategic thinking happens.
What Substantial Equivalence Means Under Rule 51(5)
Rule 51(5) states that medical devices claiming substantial equivalence to a predicate device shall not be marketed unless CLA has approved it.
The rule then provides two Explanations that define substantial equivalence precisely. These Explanations are the legal foundation of every substantial equivalence argument filed with CDSCO.
Explanation 1 states that a device shall be deemed substantially equivalent if it has the same intended use and technological characteristics as the predicate device.
Explanation 2 states that a device shall be deemed substantially equivalent if it has the same intended use and different technological characteristics — provided it can be demonstrated that the device is as safe and effective as the predicate device.
These two pathways within substantial equivalence are critically different in what they require.
The Explanation 1 pathway — same intended use, same technological characteristics — is the stronger argument. If your device does what the predicate does and uses the same fundamental technology to do it the equivalence argument is relatively straightforward. The differences between the two devices are variations within a category rather than distinctions between categories.
The Explanation 2 pathway — same intended use, different technological characteristics — requires an additional step. The manufacturer must demonstrate that despite the technological difference the device is as safe and effective as the predicate. This demonstration uses published data, bench testing, analytical comparison, and clinical evidence from the country of origin. It is a more complex argument but it opens the substantial equivalence pathway to devices that use genuinely different technology to achieve the same clinical purpose.
Explanation 2 also provides an important clarification: substantial equivalence does not mean the proposed device and predicate are identical. Equivalence is established with respect to intended use, design, energy used or delivered, materials, chemical composition, manufacturing process, performance, safety, effectiveness, labelling, biocompatibility, standards, and other characteristics as applicable.
This list is comprehensive — and deliberately so. It gives manufacturers and their advisors a structured framework for comparing their device to a predicate across multiple dimensions rather than requiring a single point of identity.
Where to Find Indian Predicate Devices
This is the most practically valuable section of this article — and the section where most manufacturers stop too early.
The CDSCO Class-Wise Device List
CDSCO publishes a class-wise list of approved medical devices on its website. This list is the starting point for every predicate device search. It contains device names, generic categories, and classification by risk class.
The search requires creativity and persistence. The device names in the CDSCO list are often generic descriptions — surgical scissors, diagnostic catheter, infusion pump, blood glucose monitoring system — rather than specific product names. A manufacturer searching for a predicate for a novel cardiac monitoring device needs to search the Class C and D lists for cardiac monitoring categories broadly defined, not just their specific product description.
The SUGAM Portal
CDSCO's SUGAM portal contains records of approved import and manufacturing licences. A systematic search of SUGAM by device category, intended use, and material type can identify approved devices that may constitute predicates.
The SUGAM search requires understanding how CDSCO categorises devices internally — which is itself a skill that develops through repeated use of the portal. Devices are categorised by generic name, not brand name. Searching by intended use in clinical language rather than product marketing language produces better results.
The Notified Device Lists
Beyond the class-wise list CDSCO has notified specific categories of devices from time to time. These notifications — published in the Official Gazette — identify device categories that are subject to MDR 2017. Reviewing these notifications provides context for understanding how CDSCO categorises device types — which in turn informs how to search for predicates in the same categories.
Thinking Laterally About Intended Use
The most important skill in predicate device searching is thinking laterally about intended use.
A manufacturer developing an AI-enabled diagnostic device for a specific condition should not search only for AI diagnostic devices. They should search for all diagnostic devices for that condition — because an older, non-AI device approved by CDSCO for the same diagnostic purpose may constitute a valid predicate under Explanation 2's same intended use, different technological characteristics pathway.
A manufacturer developing a novel wound care device using new materials should search for all wound care devices in the relevant classification category — because a wound care device approved with different materials may be a predicate under Explanation 2 if the new device can demonstrate equivalent safety and performance.
The intended use is the anchor. The technology can differ — provided equivalence is demonstrated.
Building the Substantial Equivalence Argument
Identifying a potential predicate is the beginning of the analysis. Building a credible substantial equivalence argument is the work that follows.
A well-constructed substantial equivalence argument has six components.
Predicate device identification
The full details of the predicate — CDSCO approval reference, device name, intended use as approved, material of construction, design characteristics, risk classification. This establishes the baseline against which equivalence is argued.
Intended use comparison
A side-by-side comparison of the proposed device's intended use and the predicate's intended use. Where they are identical — state that explicitly. Where they differ — explain why the differences do not change the fundamental clinical purpose and patient population served.
Technological characteristics comparison
A structured comparison across the Explanation 2 dimensions — design, energy, materials, chemical composition, manufacturing process, performance parameters, biocompatibility, applicable standards. For each dimension — identical, similar, or different — with explanation.
Performance data
For Explanation 1 pathways — bench testing data demonstrating the proposed device meets the same performance specifications as the predicate. For Explanation 2 pathways — published clinical literature, post-market surveillance data from reference markets, and bench testing demonstrating equivalent safety and effectiveness.
Safety and biocompatibility
ISO 10993 biocompatibility data for the proposed device demonstrating that any material differences from the predicate do not introduce new safety concerns. This is particularly important for Explanation 2 arguments where material differences exist.
Written equivalence argument
A formal written document addressed to CLA presenting the comparison, the evidence, and the conclusion — that the proposed device is substantially equivalent to the identified predicate within the meaning of Rule 51(5) and its Explanations. The argument must be specific, evidence-based, and directly referenced to the rule text.
The quality of this written argument materially influences whether CLA accepts the substantial equivalence claim. A generic equivalence assertion without structured comparison and supporting evidence is easily challenged. A rigorous, evidence-based argument referenced to the specific Explanation pathway being relied upon is significantly harder to reject without recorded substantive reasons.
Where the Argument Has Limitations
Honest practice requires being clear about where substantial equivalence arguments face genuine challenges.
When no Indian predicate exists
The most obvious limitation. If no device with similar intended use has ever been approved by CLA the substantial equivalence pathway is not available regardless of how sophisticated the argument. The MD-26 pathway — or the Rule 63 waiver pathway for devices with reference country approval — is the only route.
When the technology difference is too fundamental
Explanation 2 allows different technological characteristics but requires demonstration of equivalent safety and effectiveness. For devices where the technological innovation is so fundamental that no meaningful comparison to an existing predicate is possible — where the device does something categorically new rather than differently — the equivalence argument may not survive CLA scrutiny.
When CDSCO disputes the predicate identification
CLA has authority to disagree with a manufacturer's predicate identification. If CLA determines that the proposed predicate is not the first of its kind, or that the intended use comparison is not valid, or that the design characteristics are too dissimilar, the substantial equivalence claim fails and the application reverts to the MD-26 pathway.
This is why the written equivalence argument matters so much. A well-argued position that CLA rejects must be rejected for recorded reasons. Those reasons then become the basis for a refined argument or an appeal. A poorly argued position gives CLA no framework to engage with and is more easily dismissed.
The SaMD and AI Device Complexity
Software as a medical device and AI-enabled devices present particular challenges in predicate identification because the device category is relatively new in the Indian regulatory context. CDSCO's October 2025 SaMD guidance document provides some framework but the predicate device landscape for AI diagnostics, clinical decision support systems, and connected monitoring devices is still developing.
For SaMD manufacturers the intended use anchor remains valid — an AI diagnostic device for tuberculosis detection may find a predicate in an older non-AI tuberculosis diagnostic device approved by CDSCO under Rule 3(zm)'s similar intended use criterion. The Explanation 2 pathway then requires demonstrating that the AI-enabled approach is as safe and effective as the predicate non-AI approach — which published clinical validation data and regulatory approvals from reference markets can support.
The SaMD predicate argument is more complex and less tested in the Indian regulatory context. But the legal framework supports it and early-mover manufacturers who make this argument successfully establish a precedent that benefits the entire category.
The AI and Digital Health Opportunity
India's digital health and AI diagnostic sector is growing rapidly. Hundreds of companies are developing software-enabled medical devices, AI diagnostic tools, connected monitoring systems, and clinical decision support platforms.
Most of them assume they face the MD-26 pathway because their technology is novel. Many of them are wrong — because novelty of technology does not preclude substantial equivalence of intended use.
An AI-powered fundus camera for diabetic retinopathy screening has a novel AI layer. But fundus cameras for diabetic retinopathy screening are not novel — they have been approved by CDSCO. The intended use is the same. The technology differs. Explanation 2 applies.
An AI-enabled ECG analysis system uses machine learning to detect arrhythmias. ECG devices for arrhythmia detection are not novel in the Indian regulatory context. The intended use is the same. The analytical method differs. Explanation 2 applies — if the AI system can demonstrate equivalent diagnostic performance to the predicate ECG device.
For AI and digital health companies building for the Indian market the predicate device search is not just a regulatory exercise. It is a commercial strategy decision that can compress market entry by years.
What This Means for Your Regulatory Strategy
Before filing any new device application in India — whether for import or manufacturing — the predicate device analysis should be the first step.
The analysis has three possible outcomes.
Outcome 1 — a predicate exists and a strong Explanation 1 argument can be made. The fastest and cleanest pathway. MD-14 or manufacturing licence application with a robust equivalence section in the technical dossier.
Outcome 2 — a predicate exists but the Explanation 2 pathway is required due to technological differences. More documentation required. Performance comparison data needed. Still significantly faster than MD-26.
Outcome 3 — no credible predicate exists. The MD-26 pathway is confirmed as necessary. But the Rule 63 waiver provisions — reference country approval, clinical data abbreviation for special health scenario devices, post-market undertaking — should then be the immediate focus to minimise the MD-26 timeline.
Understanding which outcome applies to your device before committing to a regulatory strategy is the difference between an informed pathway decision and an expensive assumption.
The Bottom Line
Rule 51(5) of MDR 2017 creates a substantial equivalence pathway that most Indian medical device manufacturers and importers do not use — not because it does not apply to them but because they never conducted the predicate device search that would reveal it does.
The predicate device definition in Rule 3(zm) is precise. The substantial equivalence framework in Rule 51(5) Explanations 1 and 2 is structured and workable. The pathway from predicate identification to MD-14 or manufacturing licence application — bypassing years of clinical investigation — is legitimate, legally grounded, and commercially significant.
The question is not whether your device is novel. The question is whether its intended use has been served by a device previously approved by CLA.
That is the question most manufacturers never ask.
It is the question that should always be asked first.
MedReg Intel tracks regulatory developments, compliance strategy, and policy analysis relevant to India's medical device sector at medregintel.com
If you are evaluating your device's regulatory pathway in India and have not conducted a systematic predicate device search — reach out at ankur@medregintel.com for a pathway assessment before committing to MD-26.
Ankur Khare is a Biomedical Engineer and Regulatory Affairs Specialist and the founder of MedReg Intel. This article is for informational purposes and does not constitute formal regulatory or legal advice.
Comments
Post a Comment